Articles related to RESEARCH & CLINICAL TRIALS

In the randomized DECAF trial, patients undergoing cardioversion who consumed at least one caffeinated coffee daily experienced fewer clinically detected atrial fibrillation recurrences than those abstaining from caffeine. The study was modest in size and further validation is needed.

The FDA accepted Belite Bio’s NDA for tinlarebant in Stargardt disease type 1 and granted Priority Review. In the phase 3 DRAGON trial, treatment reduced atrophic retinal lesion growth by 35.7% compared with placebo, with regulatory review ongoing.

Emerging evidence suggests microbiome composition may be associated with immunotherapy response, toxicity, and outcomes in kidney cancer. Experts caution that inconsistent methodologies and limited reproducibility continue to challenge microbiome biomarker development.

A phase 1 study of mKRAS-VAX in 20 patients at high risk for PDAC showed KRAS-specific T-cell responses in most participants. No high-grade adverse events occurred, but clinical prevention data remain early.

The federal government has sharply reduced staffing and grant funding at AHRQ, the agency responsible for much of the nation’s healthcare quality and patient safety research. Supporters argue the cuts could affect future evidence generation, though the administration maintains it is restructuring agency priorities.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.